Science

Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference

Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Pyrazoles, Atopic dermatitis, Type I hypersensitivity, Ruxolitinib, Incyte, Janus kinase inhibitor, Tofacitinib
Saturday, June 12, 2021 - 10:01pm

Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting updated data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with atopic dermatitis (AD) will be presented at the upcoming 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, held on June 13, 2021.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting updated data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with atopic dermatitis (AD) will be presented at the upcoming 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, held on June 13, 2021.
  • We are pleased to be sharing new data from our Phase 3 TRuE-AD program at the RAD Virtual Conference.
  • These data provide additional insights on the potential role ruxolitinib cream could play as a treatment option for patients living with atopic dermatitis.
  • Ruxolitinib cream is currently in Phase 3 development for the treatment of adolescents and adults with atopic dermatitis (TRuE-AD) and vitiligo (TRuE-V).

Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Drugs, Health care, Health, Orphan drugs, Rituximab, Lymphoma
Saturday, June 12, 2021 - 4:45pm

CT-P10 also appeared to be generally well tolerated by patients, with adverse events (AEs) consistent with those reported for reference rituximab.

Key Points: 
  • CT-P10 also appeared to be generally well tolerated by patients, with adverse events (AEs) consistent with those reported for reference rituximab.
  • Over three quarters of patients initiated on CT-P10 achieved complete or partial response by 30 months.
  • We are encouraged by the results of the study as Truxima has demonstrated a similar IRR rate to reference rituximab.
  • Real World Clinical Effectiveness and Safety of CT-P10 in Patients with Diffuse Large B-Cell Lymphoma: Results from a European Non-Interventional Post Authorization Safety Study.

Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis

Research, Hospitals, Genetics, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Clinical medicine, Medicine, Health sciences, Orphan drugs, Gilead Sciences, Non-Hodgkin lymphoma, Breakthrough therapy, Cancer treatments, Lymphoma, Axicabtagene ciloleucel, Follicular lymphoma, Kite Pharma
Saturday, June 12, 2021 - 3:00pm

We are very encouraged by these data that suggest a significant and sustained survival benefit with Yescarta even after multiple rounds of prior treatment.

Key Points: 
  • We are very encouraged by these data that suggest a significant and sustained survival benefit with Yescarta even after multiple rounds of prior treatment.
  • In an indolent disease like follicular lymphoma, longer-term data that demonstrate durable responses are critical.
  • The continued durable benefit demonstrated by axicabtagene ciloleucel at nearly two years is exciting, and the substantial survival benefit over current therapies that were seeing in the SCHOLAR-5 analysis is encouraging.
  • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

 Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Drugs, Health care, Health sciences, Orphan drugs, Daratumumab, Multiple myeloma, Lenalidomide, Bortezomib, Dexamethasone, Janssen Pharmaceuticals, Cilag, Immunomodulatory imide drug
Saturday, June 12, 2021 - 8:01am

These results strongly support the use of daratumumab, lenalidomide and dexamethasone as a new standard of care to extend survival and improve clinical outcomes in transplant ineligible patients with newly diagnosed multiple myeloma.

Key Points: 
  • These results strongly support the use of daratumumab, lenalidomide and dexamethasone as a new standard of care to extend survival and improve clinical outcomes in transplant ineligible patients with newly diagnosed multiple myeloma.
  • Janssen Research & Development, LLC, Janssen-Cilag Ltd., Janssen Pharmaceutica NV and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Overall Survival Results With Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Transplant-ineligible Newly Diagnosed Multiple Myeloma: Phase 3 MAIA Study.
  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Drugs, Orphan drugs, Breakthrough therapy, Tyrosine kinase inhibitors, Antineoplastic drugs, Ibrutinib, Pyrazolopyrimidines, Chronic lymphocytic leukemia, Venetoclax, Obinutuzumab
Saturday, June 12, 2021 - 8:00am

Mantle cell lymphoma (MCL): As a single agent for the treatment of adult patients with relapsed or refractory MCL.

Key Points: 
  • Mantle cell lymphoma (MCL): As a single agent for the treatment of adult patients with relapsed or refractory MCL.
  • Waldenstrms macroglobulinemia (WM): As a single agent for the treatment of adult patients who have received at least one prior therapy or in first-line treatment for patients unsuitable for chemo-immunotherapy, and in combination with rituximab for the treatment of adult patients.
  • Fixed-Duration Ibrutinib Plus Venetoclax (I+V) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Phase 3 GLOW Study.
  • Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Leukemia.

NCLA ‘Anchor Bracelet’ Lawsuit Granted Class-Action Status in Fight Against NOAA’s Boat Tracking

Right to privacy, National Oceanic and Atmospheric Administration, Organizations, Earth sciences, Science
Friday, June 11, 2021 - 6:52pm

In a class-action lawsuit against the National Oceanic and Atmospheric Administration (NOAA), NCLA objects to unconstitutional and warrantless surveillance of boating operations.

Key Points: 
  • In a class-action lawsuit against the National Oceanic and Atmospheric Administration (NOAA), NCLA objects to unconstitutional and warrantless surveillance of boating operations.
  • The ruling ensures that all members of the class will benefit from the Courts rulings on these privacy issues.
  • The plaintiffs, charter boat captains and companies that take customers fishing and sightseeing off the coasts of Alabama, Florida, Louisiana, Mississippi, and Texas, say that the rule is the regulatory equivalent of an ankle bracelet (or anchor bracelet!)
  • NCLA is a nonpartisan, nonprofit civil rights group founded by prominent legal scholar Philip Hamburger to protect constitutional freedoms from violations by the Administrative State.

Virtual Solar Cup Program Culminates With Celebration of Student Winners Across Southern California

Technology, Engineering, Utilities, Manufacturing, Energy, Other Education, Other Science, Other Natural Resources, Environment, Other Technology, Primary, Secondary, Education, Natural Resources, Science, Photovoltaics, Solar Cup, Solar vehicle
Friday, June 11, 2021 - 6:53pm

At the end of the competition, instead of racing boats on Lake Skinner, teams virtually raced the solar vehicles they built with kits during the program.

Key Points: 
  • At the end of the competition, instead of racing boats on Lake Skinner, teams virtually raced the solar vehicles they built with kits during the program.
  • I am very proud of all of the teams that competed this year, Solar Cup Coordinator Julie Miller Kalbacher said.
  • The award is named for a student in the early years of Solar Cup who kept the program going at Canyon High School in Anaheim after his teacher relocated and while he was battling leukemia.
  • Bart passed away, but his spirit continues in Solar Cup with this award, Kalbacher said.

NTHU Research Team Develops Self-Healing Quantum Emitter with Unprecedented Brightness

Consumer electronics, Technology, Other Science, Research, Science, Hardware, Physical sciences, Physics, Light, Quantum electronics, Emerging technologies, Quantum chemistry, Quantum dot, Photon, Single-photon source, Quantum dot solar cell
Friday, June 11, 2021 - 6:00pm

Although perovskite quantum dots (PQDs) are rising stars among quantum emitters, their inherent instability has limited their development.

Key Points: 
  • Although perovskite quantum dots (PQDs) are rising stars among quantum emitters, their inherent instability has limited their development.
  • Their PQDs display unprecedented single-photon brightness; indeed, they have broken the world-record for the brightest room-temperature quantum emitter materiala major breakthrough for quantum information processing.
  • Lin notes that their spray-synthesized perovskite quantum emitter requires only about 1% of the excitation intensity needed by other quantum emitters, and provides a single-photon brightness exceeding 9 million photons per secondthe new world record.
  • With such excellent performancehigh single-photon brightness, high single-photon purity, and high stabilitytheir perovskite quantum emitter is a promising material for future application in quantum computing and quantum communications.

Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma

Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Biomarkers, Branches of biology, Biotechnology, Medicine, Life sciences, Chemical pathology, Medical statistics
Friday, June 11, 2021 - 3:00pm

Data from the phase 1 study of valemetostat presented at EHA informed the design of the recently initiated pivotal VALENTINE-PTCL01 study.

Key Points: 
  • Data from the phase 1 study of valemetostat presented at EHA informed the design of the recently initiated pivotal VALENTINE-PTCL01 study.
  • The first cohort will enroll patients with PTCL, and a second cohort will enroll patients with ATL.
  • The study will analyze safety endpoints including adverse events as well as pharmacokinetic and exploratory biomarker endpoints.
  • Up to 176 patients will be enrolled at approximately 70 sites in Asia, Europe, North America and Oceania.

Kyowa Kirin welcomes the decision that NICE will revisit their appraisal of the innovative systemic treatment, POTELIGEO®▼ (mogamulizumab), for adults living with two forms of ultra-rare non-Hodgkin lymphoma

Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Health, Monoclonal antibodies, National Health Service, Mogamulizumab, Kyowa Hakko Kirin, NHS Wales, Health care quality, Kirin, National Institute for Health and Care Excellence
Friday, June 11, 2021 - 1:51pm

Kyowa Kirin remains committed to finding a solution for people living with SS or MF to have access to POTELIGEO and will continue discussions with NICE and NHS England to find a resolution.

Key Points: 
  • Kyowa Kirin remains committed to finding a solution for people living with SS or MF to have access to POTELIGEO and will continue discussions with NICE and NHS England to find a resolution.
  • We strongly believe in the clinical and cost effectiveness of POTELIGEO and will continue a dialogue with NICE and NHS England.
  • We are hopeful that NICEs reassessment might bring parity with the SMCs decision to make mogamulizumab available in Scotland.
  • You can learn more about the business of Kyowa Kirin at: